Richard A. Forshee, PhD

Deputy Director
Office of Biostatistics and Pharmacovigilance, CBER, US FDA

Poster(s):

• (258) Evaluation of the Vaccinated Concurrent Comparator Methodology for Near Real Time Safety Surveillance
  Monday, August 26, 2024

  8:00 AM – 6:00 PM CEST

• (275) Linkage of Mother and Infant Records using Commercial Claims Data within the Food and Drug Administration (FDA) Biologics Effectiveness and Safety (BEST) Initiative
  Tuesday, August 27, 2024

  8:00 AM – 6:00 PM CEST

• (352) Safety of Ancestral Monovalent BNT162b2 (Pfizer-BioNTech), mRNA-1273 (Moderna), and NVX-CoV2373 (Novavax) COVID-19 Vaccines in US Children Aged 6 months to 17 years
  Wednesday, August 28, 2024

  8:00 AM – 1:30 PM CEST

• (358) Safety Monitoring of Bivalent COVID-19 mRNA Vaccines Among Recipients 6 months and Older in the United States
  Tuesday, August 27, 2024

  8:00 AM – 6:00 PM CEST

• (362) Stroke Risk Following Receipt of High-Dose/Adjuvanted Influenza Vaccinations Among U.S. Adults Aged ≥65 Years; 2016-2019
  Tuesday, August 27, 2024

  8:00 AM – 6:00 PM CEST